Newest

  • Fun Spades: Bridging Tradition and Innovation, A Journey Through Card Game Excellence

    Fun Spades rose as one of the leading forces in digital card gaming. With over millions of thousands of downloads, the app bridges tradition and innovation, offering diverse game modes, sleek interface, and social features. It celebrates the rich heritage of Spades while embracing modernity through updates and events. Looking ahead to 2024, the app's development team is gearing up for an exciting journey filled with innovative updates and features. As the realm of digital card gaming evolves, Fun Spades stands out as a captivating and intellectually stimulating choice for card game enthusiasts
  • 3X Upgrade! Meet with VOOPOO's New Super Pods ARGUS P2&G2

    VOOPOO, a leading innovator in the vaping industry, is delighted to introduce two new additions to its esteemed ARGUS Pod series - ARGUS P2 and ARGUS G2. The two new super pods come with a 3X upgrade, fully upgrading the user's vaping experience.
  • Powerful Tool in the Market - AXIS-VIP Account

    As time passes, we are quickly approaching the launch of the second phase of the Wealth Express program. Veenit Jindal, the CEO of the Asia-Pacific region at the U.S. Bancorp, after extensive market research and several rounds of negotiations, has finally selected AXIS as the brokerage firm for this collaboration. This decision will involve the public issuance of a certain number of VIP accounts. These accounts offer a range of powerful features, ensuring smooth sailing for the success of the Wealth Express program!
  • Wall Street's Indian Titan - Top Analyst Sanjay Patel

    Sanjay Patel was born in Surat.From an early age, Sanjay Patel demonstrated a strong interest in numbers and analysis. His father was an innovative teacher, and his mother was a social worker dedicated to improving the living conditions of the underprivileged.
  • Wall Street's Indian Titan - Top Analyst Sanjay Patel

    Sanjay Patel was born in Surat.From an early age, Sanjay Patel demonstrated a strong interest in numbers and analysis. His father was an innovative teacher, and his mother was a social worker dedicated to improving the living conditions of the underprivileged.
  • ISEKY Goddess Invitation NFT to be Listed on Xterio Platform, Offering Numerous Benefits

    As early as January 8th, ISEKY officially announced its entry into the Xterio platform and released a teaser video for its flagship product, ISEKY: Soul GPS. The video immediately captured the hearts of Web3 users. Within just one hour, a large number of participants flooded into ISEKY's Discord channel, and their enthusiasm even triggered Discord's protective measures, prompting ISEKY to temporarily halt new user registrations. Recently, ISEKY announced that the Goddess Invitation NFT will be listed on the Xterio platform on March 21st, once again attracting the attention of WEB3 users. Accor
  • A new giant on the global stage: ZIOPTO exchange reinvents digital trading

    ZIOPTO exchange, which has risen rapidly in the field of digital currency, recently announced its global expansion and diversification strategy. This strategy aims to further consolidate its position in the international market and promote global financial cooperation.
  • Trading innovation: ZIOPTO exchange user experience revolution

    ZIOPTO Exchange, an innovator in the field of cryptocurrency trading, recently launched a major upgrade to its user interface (UI), aiming to provide a more intuitive and easier-to-use trading experience. This upgrade marks ZIOPTO's in-depth understanding of customer needs and rapid response to market trends.
  • Powering Up Panel-Level Packaging! Capcon’s Die Bonder Wins Bulk Adoption by Internationally Leading IDM Giant

    Recently, Capcon’s large panel-level packaging die bonder,AvantGo L6 (Leo), has been adopted in bulk by an Internationally Leading IDM manufacturer and mass producer. It is believed that with the bulk application of AvantGo L6 by client, it will lead the panel-level packaging equipment towards maturity, laying a solid foundation for the development of the panel-level packaging industry and opening a new chapter of advanced packaging with low cost and high efficiency.
  • Wall Street's Indian Titan - Top Analyst Sanjay Patel

    Sanjay Patel was born in Surat.From an early age, Sanjay Patel demonstrated a strong interest in numbers and analysis. His father was an innovative teacher, and his mother was a social worker dedicated to improving the living conditions of the underprivileged.

Links

Sanyou Milestones | Super Trillion Common Light Chain Antibody Discovery Platform Launched

2023-06-09    

On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of "Sanyou Super Trillion Common Light Chain Antibody Discovery Platform" (the "platform").

 

 

As one of the nine trillion antibody discovery platforms of Sanyou, the platform features a library capacity of up to 1.12E+12 CFU. For a single target, the platform can generate hundreds of lead antibodies with diverse sequences, which can be further designed into bispecific antibodies with good drug developability, providing a feasible solution for obtaining bispecific antibodies with structures similar to the natural monoclonal antibodies.

 

C:\Users\PC\AppData\Local\Microsoft\Windows\INetCache\Content.Word\新闻稿配图2-EN.JPG

 

Bispecific antibodies are at the forefront of antibody R&D field. Compared with monoclonal antibodies, bispecific antibodies possess one additional antigen binding arm, which brings stronger specificity and better targeting. As of March of 2023, 436 bispecific antibody drug candidates have advanced to clinical trials worldwide, and 10 bispecific antibody drugs had been approved for marketing, with sales of more than 5 billion USD.

 

The antibody library of the platform was established in a rigorous way. To be specific, 2 common light chains were selected through alignment and screening of 1800+ light chain sequences, validation of 25 proof-of-concept libraries, and antibody characterization and analysis of 12 light chains. The bispecific antibodies generated by this platform exhibit good drug developability, and the heavy chains possess natural antibody properties and high diversity. The platform employs the knob-into-hole technology to ensure the correct pairing in the process of bispecific antibody formation and eliminate the mismatch. These common light chain antibodies are suitable for multiple application scenarios, such as bispecific antibody development, dual-targeting or bi-paratopic ADC, and therapeutic or detection antibodies.

 

Following the customer-oriented concept, the platform provides two types of services, i.e., library screening and library integration, making it not only suitable for the R&D service of individual projects, but also for customers’ integration into their own platforms with the exclusively customized common light chain libraries.

It is believed that the launch of the platform will provide customers with great assistance in overcoming the difficulties in the R&D of bispecific antibody drugs, reducing the challenges in the development of bispecific antibody drugs, and greatly accelerating the R&D of bispecific antibodies.

 

About Sanyou Bio

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biological drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make it easy to discover innovative biological drugs anywhere”.

 

Sanyou has established an integrated innovative biological drug R&D laboratory of twenty thousand square meters with advanced facilities, and has built three industry-leading innovative technology platforms featured by “super-trillion, integration, and intelligence" , which are comprised of more than 50 sub-platforms with the core innovative super-trillion phage display platform, and supported by platforms of material preparation, antibody discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc.

 

Sanyou’s proprietary platform and technology are in continuous optimisation,they launch from time to time upgrades and new version of services and technologies based on principles of innovation, outstanding and reliability. The company has established friendly business collaboration with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide.

 

Company:Sanyou Biopharmaceuticals (Shanghai) Co., Ltd.

Contact Person:Guohong He

Email:guohong.he@sanyoubio.com

Website:www.sanyoubio.com

Telephone:+86-400-821-0776

City:3/F, Building 6, No. 188 Xinjunhuan Road, Minhang District, Shanghai, China ,201114

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.
Back to top
©copyright 2009-2020 Lome Times       Contact Us   SiteMap